Abbott Laboratories (USA) holds 2 active US FDA Type II Drug Master Files and 34 inactive, has DMF or CEP filings on record for 19 active ingredients and is linked to 3 FDA-registered manufacturing sites. 8 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Abbott Laboratories: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/abbott-laboratories

Overview

Abbott Laboratories, a global healthcare company, focuses on the research and development, manufacture, and sale of a broad and diversified line of health care products. It operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Core services & business areas

Pharmaceutical SupplyRegulatory AffairsMarketingDistribution

Therapeutic areas

CardiovascularDiabetes CareDiagnosticsNeuromodulationNutritionPharmaceuticals

Active ingredients with DMF or CEP filings

Substances for which Abbott Laboratories holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Abbott Laboratories holds 2 active (36 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • LACTULOSE CONCENTRATE USPActive1993-03-19
  • VERAPAMIL HYDROCHLORIDEActive1987-06-04
  • HYDROCODONE/ACETAMINOPHEN EXTENDED RELEASE TABLETSInactive2006-08-04
  • FENOFIBRATE SPRAY GRANULATION INTERMEDIATEInactive2003-10-10
  • AMIKACIN SULFATEInactive1998-09-01
  • CLINDAMYCIN HYDROCHLORIDEInactive1998-09-01
  • BUTORPHANOL TARTRATE USPInactive1998-03-27
  • TROMETHAMINE,USPInactive1997-08-29
  • SIMETHICONE COATED CELLULOSE (SONORX); MANFACTURED IN NORTH CHICAGO, ILInactive1996-08-20
  • D-CHIRO-INOSITOLInactive1996-06-28
  • MSI-78Inactive1995-07-07
  • ATRACURIUM BESYLATEInactive1994-10-21
  • AMRINONEInactive1994-09-14
  • SEMI-WORKS AREA IN QUEENBOROUGH, KENT, UNITED KINGDOMInactive1993-05-28
  • PROTIRELIN (TRH)Inactive1993-05-14
  • FACILITIES AND OPERATING PROCEDURES IN LATINA, ITALY (LABORATORI ABBOTT S.P.A.)Inactive1993-04-17
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ETHRANE IN QUEENBOUROUGH, KENT, ENGLAND.Inactive1993-03-23
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN NORTH CHICAGO, ILLINOIS.Inactive1992-05-29
  • GLIPIZIDEInactive1991-10-22
  • 9-(S)-ERYTHROMYCYLAMINEInactive1991-07-30
  • ARBUTAMINEInactive1991-05-31
  • FACILITIES AND OPERATING PROCEDURES IN QUEENBOROUGH, ENGLANDInactive1991-04-29
  • FENTANYLInactive1991-03-18
  • RAPAMYCIN CRUDE OILInactive1991-01-02
  • DOBUTAMINE HYDROCHLORIDEInactive1990-06-05
  • HYROCHLOROQUINE SULFATEInactive1990-03-22
  • PENTAMIDINE ISETHIONATEInactive1989-08-15
  • FACILITIES LOCATED IN QUEENBOROUGH, KENT, UKInactive1989-05-16
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN QUEENBOURGH, KENT, UNITED KINGDOM.Inactive1989-03-01
  • ETHRANE (ENFLURANE)Inactive1986-04-23
  • METHYLPREDNISOLONE HEMISUCCINATEInactive1985-09-03
  • VERAPAMIL AS MNFG IN N.CHICAGO, ILLINOISInactive1983-03-31
  • MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MCPHERSON, KANSAS.Inactive1977-02-16
  • ESTERIFIED ESTROGENS USPInactive1976-11-02
  • SUCCINYLCHOLINE CHLInactive1971-11-17
  • 2-(2-FORMYLHYDRAZINO)-4-(5-NITRO-2-FURYL)-THIAZOLE (AS-L7665)&A-2L203Inactive1963-08-08

Registered manufacturing sites (3)

Physical sites registered with the US FDA and resolved to Abbott Laboratories, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

8 FDA enforcement records linked to this company.

  • recall — Class II2013-01-09

    Labeling: Error on Declared Strength. Product labeled to contain 150 mcg tablets actually contained 75 mcg tablets.

  • recall — Class II2012-10-03

    Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

  • recall — Class II2012-10-03

    Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

  • recall — Class II2012-10-03

    Defective Container: A number of Synthroid bottles have a localized thin wall defect on the bottom which may potentially impact the stability of the tablets.

  • recall — Class II2012-06-27

    CGMP Deviations: There is potential that Abbott's third party manufacturer, Hospira, may have applied a foreign (incorrect) stopper to vials in a specific lot of Zemplar Injection.

  • 4832011-07-15

    Complaint Handling Procedure

  • 4832010-12-16

    Failure by applicant to report ADE

  • warning_letter2009-07-14

    FDA Warning Letter (drug product)

For suppliers

Is this Abbott Laboratories?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.